Skip to main content

Month: August 2024

Protect Pharmaceutical Corp. (PRTT) Finalizes the Merger with KARINCA Logistics

ANKARA, Turkey, Aug. 28, 2024 (GLOBE NEWSWIRE) — Protect Pharmaceutical Corp. (OTC: PRTT) ($PRTT) (“Company”) announces it completed the necessary documentation to finalize the merger with KARINCA Logistics – www.karincalogistics.com. PRTT’s Management believes that the KARINCA Logistics merger should add substantial value to the Company’s overall operations, and it brings a talent pool of professionals, dedicated to the successful integration of the combined business operations. KARINCA Logistics brings a large network of operations, many very valuable routes, and opens sales opportunities throughout Europe and Asia. To complete the merger, the Company issued 1,000,000 additional Preferred Shares, which have 100 to 1 common share voting rights but are not convertible to common shares. There was no common share dilution to...

Continue reading

Taboola Opens Maximize Conversions AI Bidding Technology to All Advertisers to Drive More Conversions and Lower Campaign Costs; Offering Reaches Milestone Adoption with 100% Increase in Advertiser Campaigns Quarter Over Quarter

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, today announced its performance advertising-focused bidding technology, Maximize Conversions, is now available for all advertisers. Previously, thousands of advertisers have used Maximize Conversions, which is an AI-powered technology that enables Taboola advertisers to drive more conversions and lower cost for campaigns. Through this offering, Taboola is automating the bidding process for campaigns, allowing advertisers to remove the complexities of manual optimizations. This means they can simply share their budget and marketing objectives, and the algorithm will manage their campaigns in the most efficient and effective way possible within the set cost. Many have achieved 110% increase in conversions...

Continue reading

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

GAITHERSBURG, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule. Nasdaq sent notice to the Company that it had regained compliance as of August 27, 2024, after it traded above $1.00 per share for ten consecutive trading days. About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation...

Continue reading

Broadcom Launches Rally Anywhere, the On-Premises Version of its Leading Enterprise Agility Platform

Full ValueOps Value Stream Management Solution Now Available as SaaS or On-Premises LAS VEGAS, Aug. 28, 2024 (GLOBE NEWSWIRE) — VMware Explore 2024 — Broadcom Inc. (NASDAQ: AVGO) today announced the launch of Rally® Anywhere, the on-premises offering of Rally, its industry-leading enterprise agility platform. Designed to meet the unique needs of global organizations, Rally Anywhere enables teams to plan, prioritize, manage, track, and measure at every level of the organization to deliver maximum customer value while remaining compliant with strict data sovereignty policies and heightened security demands. “We are committed to empowering enterprise teams with the tools they need to succeed, and Rally Anywhere exemplifies this commitment. With its focus on enterprise security, data sovereignty, and support for global value...

Continue reading

CORRECTION: Abercrombie & Fitch Co. Reports Second Quarter Fiscal 2024 Results

NEW ALBANY, Ohio, Aug. 28, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline on Wednesday, August 28th by Abercrombie & Fitch Management Co. (NYSE: ANF), please note that in the first bullet under Fiscal 2024 Third Quarter Outlook, the fiscal 2023 net sales growth level has been corrected to $1.06 billion. The corrected release follows:Record second quarter net sales of $1.1 billion, up 21% from last year with comparable sales growth of 18% Broad-based net sales growth across regions and brands, with Abercrombie brands growth of 26% and Hollister brands accelerating to growth of 17% Operating margin expands 590 basis points to 15.5%, with record second quarter operating income of $176 million Further strengthened balance sheet with redemption of all its outstanding 8.75% senior secured notes and amendment...

Continue reading

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York. Dr. Malte Peters, Hookipa’s Chief Executive Officer, and Terry Coelho, Executive Vice President & Chief Financial Officer will be hosting one-on-one meetings with investors during the conference. In addition, Dr. Peters will participate in a Fireside Chat on Monday, September 9, 2024 at 1:30 p.m. ET. The fireside chat will be available via webcast through the following link: https://journey.ct.events/view/a5640121-61ef-4c2b-8017-b6b346ca2547 A...

Continue reading

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash TEL AVIV, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that it has finalized an Exclusive Patent License Agreement (“the License Agreement”) with Polyrizon Ltd. (“Polyrizon”), for the out-licensing of its SCI-160 program (the “Assets”) for the treatment of pain. As announced on August 15, 2024, Polyrizon will receive exclusive, royalty-bearing global license to develop and sublicense the Assets. In exchange, SciSparc would...

Continue reading

ECD Auto Design’s Newest Beach Runner Rolls Off the Line, Ready for the Coast

KISSIMMEE, Fla., Aug. 28, 2024 (GLOBE NEWSWIRE) — ECD Automotive Design, renowned for its bespoke custom luxury vehicles, is thrilled to announce the launch of its latest masterpiece: The Beach Runner 3. The third vehicle in the Beach Runner series is meticulously crafted to combine the ruggedness of a classic Land Rover with the innovative customization of a coastal and beach focused vehicle. View high-resolution images and video HERE. Built for coastal and beach living and finished in a stunning Cornish Cream gloss paint, the Beach Runner 3 is sure to turn heads just as its first two predecessors. The vehicle features a cohesive body color scheme, including wheel spats, grille, light surrounds, hinges, Optimill air intakes, and a custom roll cage. The power retractable side steps, rear light guards and work light are painted...

Continue reading

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three and six months ended June 30, 2024, the highlights of which are included in this news release. The Company’s complete set of condensed interim consolidated financial statements for the three and six months ended June 30, 2024, and accompanying management’s discussion and analysis for the period can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca. Key Business Highlights On April 1, 2024, the Company entered into a contract research organization services...

Continue reading

Award-Winning Media and Creator company Underknown Acquires “Animalogic” from Blue Ant Media

Underknown Buys Animalogic from Blue Ant MediaWebby-award-winning digital-first media company Underknown announces today it has purchased the popular YouTube channel “Animalogic” from international production studio, rights business and channel operator, Blue Ant Media.The acquisition sees “Animalogic” join the Underknown suite of video channels which includes the popular shows: What If, Aperture, and How to Survive. This deal marks the second acquisition in three years for Underknown as they expand their portfolio of brands.TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) — Webby-award-winning digital-first media company Underknown announces today it has purchased the popular YouTube channel “Animalogic” from international production studio, rights business and channel operator, Blue Ant Media. The acquisition sees “Animalogic”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.